Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.1K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.1K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

906
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
906
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

3.0K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
3.0K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.8K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.8K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.0K
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

48
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
48

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibroblasts: a diverse population of cells balancing homeostasis, wound healing, regeneration, inflammation, fibrosis, and cancer across organs.

JCI insight·2026
Same author

Circulating CTHRC1 levels are associated with IPF disease severity and survival.

Thorax·2026
Same author

Lung adventitial fibroblasts support type 2 Tregs to shape the response to influenza infection.

bioRxiv : the preprint server for biology·2026
Same author

Inhibition of the EBF1-ITGB8 Axis in Bone Marrow Niche Ameliorates Hallmarks of Myelofibrosis.

bioRxiv : the preprint server for biology·2026
Same author

Alveolar Type II Cell-derived MMP1 <sup>high</sup> basal cells promote destructive microcysts in idiopathic pulmonary fibrosis.

bioRxiv : the preprint server for biology·2026
Same author

β-III tubulin identifies anti-fibrotic state of pericytes in pulmonary fibrosis.

Research square·2025

Related Experiment Video

Updated: May 2, 2026

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

1.1K

ROCKing pulmonary fibrosis.

Dean Sheppard1

  • 1Lung Biology Center, Department of Medicine, UCSF, San Francisco, California 94143-2922, USA. Dean.Sheppard@ucsf.edu

The Journal of Clinical Investigation
|February 26, 2013
PubMed
Summary
This summary is machine-generated.

This case study discusses treatment options for a 76-year-old man diagnosed with idiopathic pulmonary fibrosis (IPF). The focus is on managing his progressive shortness of breath and declining lung function.

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.2K
Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.4K

Related Experiment Videos

Last Updated: May 2, 2026

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

1.1K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.2K
Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.4K

Area of Science:

  • Pulmonology
  • Interstitial Lung Diseases

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease.
  • Patients often present with shortness of breath and reduced lung function.

Purpose of the Study:

  • To outline treatment recommendations for a patient with advanced idiopathic pulmonary fibrosis.
  • To consider management strategies for elderly patients ineligible for lung transplantation.

Main Methods:

  • A clinical vignette detailing a 76-year-old male patient with IPF.
  • Review of diagnostic findings including lung biopsy and pulmonary function tests (DLCO, TLC).

Main Results:

  • The patient exhibits advanced disease with DLCO at 45% and TLC at 40% of predicted.
  • Lung transplantation is not a viable option due to age.

Conclusions:

  • Treatment decisions for IPF must consider patient age, disease severity, and transplant eligibility.
  • Further management may involve pharmacotherapy and supportive care to improve quality of life.